pretomanid: Clinical Trials

24 trials of pretomanid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 5 recruiting, 2 active not recruiting, 2 suspended. 24 Phase 2, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 224Completed 12, Recruiting 5, Active not recruiting 2, Suspended 2, Not yet recruiting 1, Terminated 1, Unknown 1
Phase 36Completed 3, Active not recruiting 1, Recruiting 1, Unknown 1

Follow pretomanid: new trials by email Literature Review of pretomanid trials Research Report on pretomanid

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary
Phase 2Not yet recruitingTASK Applied Science1352026-09-252026-09-25
Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB
sorfequiline, Pretomanid, Linezolid - Tuberculosis, Pulmonary
Phase 2RecruitingGlobal Alliance for TB Drug Development1002026-07-092026-08-19
Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis
Bedaquiline, pretomanid, linezolid, Nicotinamide (NAM) - Drug Susceptible Pulmonary Tuberculosis
Phase 2SuspendedGates Medical Research Institute1652026-04-172026-08-10
Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis
Bedaquiline, pretomanid and TBD09, Bedaquiline, pretomanid and linezolid - Drug Susceptible Pulmonary Tuberculosis
Phase 2RecruitingGates Medical Research Institute1502026-04-142026-07-30
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2 / Phase 3RecruitingUniversity of California, San Francisco4002025-10-032026-09-02
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis
Phase 2SuspendedNational Institute of Allergy and Infectious Diseases (NIAID)3412025-03-112026-11-02
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis
Phase 2RecruitingUniversity College, London25002024-01-092026-10-15
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis
Phase 2Active not recruitingGlobal Alliance for TB Drug Development3092023-10-312026-06-24
A Pan-TB Regimen Targeting Host and Microbe
Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis
Phase 2 / Phase 3Active not recruitingThe Aurum Institute NPC3522023-07-282025-05-28
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis
Phase 2TerminatedGates Medical Research Institute932023-07-262026-05-20
PanACEA - STEP2C -01
BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis
Phase 2RecruitingMichael Hoelscher3902023-04-142025-10-07
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
GSK3036656, Bedaquiline, Delamanid - Tuberculosis
Phase 2CompletedGlaxoSmithKline1272022-07-262026-06-17
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2CompletedGlobal Alliance for TB Drug Development262021-09-162025-01-17
Economic Evaluation of New MDR TB Regimens
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands732020-10-202024-04-22
PRACTECAL-PKPD Sub Study
Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3UnknownMedecins Sans Frontieres, Netherlands2402019-08-062021-05-14
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Phase 2 / Phase 3CompletedGlobal Alliance for TB Drug Development4552018-07-302026-08-27
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Phase 2 / Phase 3CompletedMedecins Sans Frontieres, Netherlands5522017-01-012024-05-01
Assessing PA-824 for Tuberculosis (the APT Trial)
PA-824, Rifampin, Rifabutin - Pulmonary Tuberculosis
Phase 2CompletedJohns Hopkins University1572015-04-292023-07-18
A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
PA-824, bedaquiline, moxifloxacin - Tuberculosis
Phase 2CompletedGlobal Alliance for TB Drug Development2402014-10-232019-07-26
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
TMC207 (J), PA-824 (PA), pyrazinamide (Z) - Pulmonary Tuberculosis
Phase 2CompletedGlobal Alliance for TB Drug Development1052012-10-012016-12-13

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Tuberculosis, Pulmonary (20)  ·  Tuberculosis (12)  ·  Tuberculosis, Multidrug-Resistant (8)  ·  Extensively Drug-Resistant Tuberculosis (4)

Sponsors

Global Alliance for TB Drug Development (10)  ·  Gates Medical Research Institute (3)  ·  Medecins Sans Frontieres, Netherlands (3)  ·  GlaxoSmithKline (1)  ·  Johns Hopkins University (1)  ·  Michael Hoelscher (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  TASK Applied Science (1)  ·  The Aurum Institute NPC (1)  ·  University College, London (1)  ·  University of California, San Francisco (1)

Countries

South Africa (22)  ·  Tanzania (8)  ·  Uganda (7)  ·  Philippines (4)  ·  Belarus (3)  ·  Georgia (3)  ·  Vietnam (3)  ·  Brazil (2)  ·  Malawi (2)  ·  Mozambique (2)  ·  Peru (2)  ·  Uzbekistan (2)  ·  Botswana (1)  ·  Gabon (1)  ·  Haiti (1)

Top investigators

Andreas Diacon, MD (3)  ·  Rodney Dawson, MD (3)  ·  Andreas Diacon (1)  ·  Antonio Lombardi, MD (1)  ·  Bern Nyang'wa, MB BS, MPH (1)  ·  Bern-Thomas Nyang'wa, MD (1)  ·  Fairoez Ryklief, MBBChB (1)  ·  Kelly Dooley, MD, PhD (1)  ·  Kelly E Dooley, MD PhD (1)  ·  Michael Hoelscher, Prof Dr. (1)  ·  Morounfolu Olugbosi (1)

Results publications

PMID 22430968, PMID 22828481, PMID 25622149, PMID 25795076, PMID 31732485, PMID 33229425, PMID 34489274, PMID 35698158, PMID 36455068, PMID 36546625, PMID 37980911, PMID 38768617, PMID 38842323, PMID 39651910, PMID 40195983, PMID 40817073, PMID 41616265, PMID 41749341, PMID 41917253, PMID 42270675